Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study

被引:1
作者
Sunami, Kazutaka [1 ]
Murakami, Hiroyuki [1 ]
Tagashira, Hisashi [2 ]
Ueda, Hiroko [1 ]
Moriyama, Takashi [1 ]
Ishikawa, Tatsunori [1 ]
Yoshioka, Takanori [1 ]
Makita, Masanori [1 ]
机构
[1] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Kita Ku, 1711-1 Tamasu, Okayama 7011192, Japan
[2] Natl Hosp Org Okayama Med Ctr, Dept Pharm, Kita Ku, 1711-1 Tamasu, Okayama 7011192, Japan
关键词
Daratumumab; Multiple myeloma; Relapsed; Refractory; JAPANESE PATIENTS; EFFICACY; DEXAMETHASONE; MONOTHERAPY; MULTICENTER; BORTEZOMIB; SAFETY;
D O I
10.1007/s10147-020-01754-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Significant advancements have been achieved in the quality of treatment for relapsed/refractory multiple myeloma (RRMM). Currently, daratumumab (DARA) is a highly effective drug widely used for RRMM; however, the knowledge on its efficacy and safety in Japanese patients remains limited. Accordingly, we aimed to evaluate the efficacy and safety of DARA therapy for RRMM. Methods We reviewed the medical records of patients who received DARA combination therapy and evaluated its efficacy and safety in our hospital. Results DARA was administered to 44 patients between October 2017 and March 2019. The median number of previous therapies was three (range 1-9). The rates of >= complete response and overall response were 27.3% and 61.4%, respectively. The median progression-free survival (PFS) duration was 12.3 months [95% confidence interval (CI) 5.1 to not reached (NR)] and estimated 2-year overall survival rate was 63.7% (95% CI 46.9-76.5%). In the multivariate analysis, patients with >= three previous lines of therapy and mass lesions showed significantly shorter PFS durations. The observed grade 3/4 adverse events (>= 10%) included neutropenia (59.0%), thrombocytopenia (29.5%), anemia (36.4%), lymphopenia (38.6%) and febrile neutropenia (18.2%). None of the patients discontinued DARA therapy in spite of these AEs. Conclusion DARA is an effective treatment option for most patients and is tolerable. However, patients with heavy treatment before DARA therapy and mass lesions are likely to show poorer outcomes. Our findings suggest the use of DARA therapy early in the course of the disease.
引用
收藏
页码:2151 / 2157
页数:7
相关论文
共 19 条
[11]   Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials [J].
Lakshman, Arjun ;
Abeykoon, Jithma P. ;
Kumar, Shaji K. ;
Rajkumar, S. Vincent ;
Dingli, David ;
Buadi, Francis K. ;
Gonsalves, Wilson I. ;
Leung, Nelson ;
Dispenzieri, Angela ;
Kourelis, Taxiarchis V. ;
Go, Ronald S. ;
Lacy, Martha Q. ;
Hobbs, Miriam A. ;
Lin, Yi ;
Warsame, Rahma ;
Lust, John ;
Fonder, Amie L. ;
Hwa, Yi L. ;
Hayman, Suzanne R. ;
Russell, Stephen J. ;
Kyle, Robert A. ;
Gertz, Morie A. ;
Kapoor, Prashant .
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (11) :1146-1155
[12]   Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial [J].
Lonial, Sagar ;
Weiss, Brendan M. ;
Usmani, Saad Z. ;
Singhal, Seema ;
Chari, Ajai ;
Bahlis, Nizar J. ;
Belch, Andrew ;
Krishnan, Amrita ;
Vescio, Robert A. ;
Victoria Mateos, Maria ;
Mazumder, Amitabha ;
Orlowski, Robert Z. ;
Sutherland, Heather J. ;
Blade, Joan ;
Scott, Emma C. ;
Oriol, Albert ;
Berdeja, Jesus ;
Gharibo, Mecide ;
Stevens, Don A. ;
LeBlanc, Richard ;
Sebag, Michael ;
Callander, Natalie ;
Jakubowiak, Andrzej ;
White, Darrell ;
de la Rubia, Javier ;
Richardson, Paul G. ;
Lisby, Steen ;
Feng, Huaibao ;
Uhlar, Clarissa M. ;
Khan, Imran ;
Ahmadi, Tahamtan ;
Voorhees, Peter M. .
LANCET, 2016, 387 (10027) :1551-1560
[13]   Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology [J].
Malavasi, Fabio ;
Deaglio, Silvia ;
Funaro, Ada ;
Ferrero, Enza ;
Horenstein, Alberto L. ;
Ortolan, Erika ;
Vaisitti, Tiziana ;
Aydin, Semra .
PHYSIOLOGICAL REVIEWS, 2008, 88 (03) :841-886
[14]   Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma [J].
Overdijk, Marije B. ;
Verploegen, Sandra ;
Bogels, Marijn ;
van Egmond, Marjolein ;
van Bueren, Jeroen J. Lammerts ;
Mutis, Tuna ;
Groen, Richard W. J. ;
Breij, Esther ;
Martens, Anton C. M. ;
Bleeker, Wim K. ;
Parren, Paul W. H. I. .
MABS, 2015, 7 (02) :311-320
[15]   Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma [J].
Palumbo, Antonio ;
Chanan-Khan, Asher ;
Weisel, Katja ;
Nooka, Ajay K. ;
Masszi, Tamas ;
Beksac, Meral ;
Spicka, Ivan ;
Hungria, Vania ;
Munder, Markus ;
Mateos, Maria V. ;
Mark, Tomer M. ;
Qi, Ming ;
Schecter, Jordan ;
Amin, Himal ;
Qin, Xiang ;
Deraedt, William ;
Ahmadi, Tahamtan ;
Spencer, Andrew ;
Sonneveld, Pieter .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) :754-766
[16]   Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis [J].
Pick, Marjorie ;
Vainstein, Vladimir ;
Goldschmidt, Neta ;
Lavie, David ;
Libster, Diana ;
Gural, Alexander ;
Grisariu, Sigal ;
Avni, Batia ;
Ben Yehuda, Dina ;
Gatt, Moshe E. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (05) :494-501
[17]   Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 [J].
Rajkumar, S. Vincent ;
Harousseau, Jean-Luc ;
Durie, Brian ;
Anderson, Kenneth C. ;
Dimopoulos, Meletios ;
Kyle, Robert ;
Blade, Joan ;
Richardson, Paul ;
Orlowski, Robert ;
Siegel, David ;
Jagannath, Sundar ;
Facon, Thierry ;
Avet-Loiseau, Herve ;
Lonial, Sagar ;
Palumbo, Antonio ;
Zonder, Jeffrey ;
Ludwig, Heinz ;
Vesole, David ;
Sezer, Orhan ;
Munshi, Nikhil C. ;
San Miguel, Jesus .
BLOOD, 2011, 117 (18) :4691-4695
[18]   Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study [J].
Suzuki, Kenshi ;
Dimopoulos, Meletios A. ;
Takezako, Naoki ;
Okamoto, Shinichiro ;
Shinagawa, Atsushi ;
Matsumoto, Morio ;
Kosugi, Hiroshi ;
Yoon, Sung-Soo ;
Huang, Shang-Yi ;
Qin, Xiang ;
Qi, Ming ;
Iida, Shinsuke .
BLOOD CANCER JOURNAL, 2018, 8
[19]   Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma [J].
Usmani, Saad Z. ;
Weiss, Brendan M. ;
Plesner, Torben ;
Bahlis, Nizar J. ;
Belch, Andrew ;
Lonial, Sagar ;
Lokhorst, Henk M. ;
Voorhees, Peter M. ;
Richardson, Paul G. ;
Chari, Ajai ;
Sasser, A. Kate ;
Axel, Amy ;
Feng, Huaibao ;
Uhlar, Clarissa M. ;
Wang, Jianping ;
Khan, Imran ;
Ahmadi, Tahamtan ;
Nahi, Hareth .
BLOOD, 2016, 128 (01) :37-44